Business
20/20 Biolabs develops and commercializes AI-powered, laboratory-based blood tests for early detection and prevention of cancers and chronic diseases.
20/20 Biolabs grew revenue 16.7% and narrowed losses, but equity fell negative and accounting scores stayed stressed.
The read at a glance✓ Audited against SEC data
- Business mix — AI-powered lab blood testsNote
- Revenue — Revenue grew 16.7% to $2.05MOK
- Profitability — Net loss was $3.74MWatch
- Cash — Cash from ops was -$1.92MWatch
- Balance sheet — Equity fell to -$19KWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distress; EQ distressWatch
Where the revenue comes from
Fiscal 2025, as 20/20 Biolabs, Inc. reports it. History and quarterly detail are in the app.
- One Test$1.8M
- Bio Check$152K
- CLI Ax$89K
Latest filings
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-17
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about 20/20 Biolabs, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.